PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Novartis’ remibrutinib shows promise for patients with CSU

Highly selective inhibitor therapy treats patients with chronic spontaneous urticaria.

Novartis has shared positive top-line results from two late-stage studies analysing remibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, among patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.

Remibrutinib is a highly selective inhibitor that effectively blocks the BTK cascade and prevents the release of histamines that trigger itches, hives, welts and swelling.

The phase 3 REMIX-1 and REMIX-2 studies duly met their primary endpoint of absolute change from baseline in weekly urticaria activity score (UAS) at week 12, demonstrating clinically significant improvements in disease activity.

Meanwhile, remibrutinib also showed a prompt onset of action, as illustrated by the improvement of UAS at week two in both trials. This data supports the potential of remibrutinib as an effective and fast-acting oral treatment option for those uncontrolled by first-line H1-antihistamines.

Shreeram Aradhye, president of global drug development and chief medical officer at Novartis, was optimistic about the data: “CSU is a distressing and unpredictable disease, and patients urgently need effective, convenient and well-tolerated treatments that can provide rapid and sustained relief from the relentless itching and deep tissue swelling that greatly impact their daily lives.

“These positive top-line results from the phase 3 REMIX studies confirm that remibrutinib, a highly selective BTK inhibitor, has the potential to be a first-in-class, oral treatment for people living with CSU whose symptoms are refractory despite the use of antihistamines.”

Presently, H1-antihistamines are the first-line treatment in CSU. Around 60% of patients, however, are inadequately controlled with antihistamines alone and continue to live with difficult symptoms.

Individuals currently enrolled in REMIX-1 and REMIX-2 will continue to receive treatment up to week 52 and will also have the opportunity to continue in a long-term extension study. Novartis intends to submit to global health authorities next year.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026